• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

间充质干细胞/基质细胞疗法在特应性皮炎和慢性荨麻疹中的免疫和临床观点。

Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints.

机构信息

Miraecellbio Co., Ltd., Seoul, Korea.

Department of Biomedical Sciences, College of Natural Science, The Graduate School of Dong-A University, Busan, Korea.

出版信息

Stem Cell Res Ther. 2021 Oct 11;12(1):539. doi: 10.1186/s13287-021-02583-4.

DOI:10.1186/s13287-021-02583-4
PMID:34635172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8503727/
Abstract

Allergic diseases are immune-mediated diseases. Allergies share a common immunopathogenesis, with specific differences according to the specific disease. Mesenchymal stem/stromal cells (MSCs) have been applied to people suffering from allergic and many other diseases. In this review, the immunologic roles of MSCs are systemically reviewed according to disease immunopathogenesis from a clinical viewpoint. MSCs seem to be a promising therapeutic modality not only as symptomatic treatments but also as causative and even preventive treatments for allergic diseases, including atopic dermatitis and chronic urticaria.

摘要

过敏性疾病是免疫介导的疾病。过敏具有共同的免疫发病机制，但根据具体疾病存在特定差异。间充质干细胞（MSCs）已应用于过敏和许多其他疾病患者。从临床免疫发病机制的角度来看，本综述系统地综述了 MSCs 的免疫作用。MSCs 似乎不仅是一种有前途的对症治疗方法，而且是一种有前途的病因甚至预防治疗方法，可用于治疗过敏性疾病，包括特应性皮炎和慢性荨麻疹。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/d68388c40b45/13287_2021_2583_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/17b5b37e7eaa/13287_2021_2583_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/f439e252a031/13287_2021_2583_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/27da93697992/13287_2021_2583_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/d68388c40b45/13287_2021_2583_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/17b5b37e7eaa/13287_2021_2583_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/f439e252a031/13287_2021_2583_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/27da93697992/13287_2021_2583_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a387/8504012/d68388c40b45/13287_2021_2583_Fig4_HTML.jpg

相似文献

1
Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints.间充质干细胞/基质细胞疗法在特应性皮炎和慢性荨麻疹中的免疫和临床观点。
Stem Cell Res Ther. 2021 Oct 11;12(1):539. doi: 10.1186/s13287-021-02583-4.
2
Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: Atopic dermatitis and psoriasis.间充质干细胞及其衍生物在常见皮肤炎症性疾病中的治疗作用：特应性皮炎和银屑病。
Front Immunol. 2023 Feb 20;14:1092668. doi: 10.3389/fimmu.2023.1092668. eCollection 2023.
3
Atopic dermatitis and skin allergies - update and outlook.特应性皮炎和皮肤过敏——更新与展望。
Allergy. 2013 Dec;68(12):1509-19. doi: 10.1111/all.12324. Epub 2013 Nov 26.
4
Disease-specific primed human adult stem cells effectively ameliorate experimental atopic dermatitis in mice.特异性疾病诱导的人成体干细胞有效改善了实验性特应性皮炎小鼠的症状。
Theranostics. 2019 May 26;9(12):3608-3621. doi: 10.7150/thno.32945. eCollection 2019.
5
Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria.成人特应性皮炎的治疗管理：与银屑病和慢性荨麻疹的比较。
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2339-2345. doi: 10.1111/jdv.16329. Epub 2020 Apr 27.
6
Recent advance in mesenchymal stem cells therapy for atopic dermatitis.间充质干细胞治疗特应性皮炎的最新进展。
J Cell Biochem. 2023 Feb;124(2):181-187. doi: 10.1002/jcb.30365. Epub 2022 Dec 28.
7
Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling.吡美莫司通过调节 NFAT-COX2 信号通路干扰特应性皮炎患者间充质干细胞的治疗效果。
Stem Cell Res Ther. 2021 Aug 28;12(1):482. doi: 10.1186/s13287-021-02547-8.
8
Ocular allergies.眼部过敏
Curr Allergy Asthma Rep. 2001 Jul;1(4):389-96. doi: 10.1007/s11882-001-0053-z.
9
Enhanced therapeutic effects of human mesenchymal stem cells transduced with superoxide dismutase 3 in a murine atopic dermatitis-like skin inflammation model.超氧化物歧化酶 3 转染的人骨髓间充质干细胞在小鼠特应性皮炎样皮肤炎症模型中的增强治疗效果。
Allergy. 2018 Dec;73(12):2364-2376. doi: 10.1111/all.13594. Epub 2018 Oct 11.
10
Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.严重哮喘、特应性皮炎和慢性荨麻疹的免疫生物学治疗。
Allergy Asthma Proc. 2019 Nov 1;40(6):485-489. doi: 10.2500/aap.2019.40.4277.

引用本文的文献

1
Therapeutic roles of natural and engineered mesenchymal stem cells and extracellular vesicles in atopic dermatitis.天然和工程化间充质干细胞及细胞外囊泡在特应性皮炎中的治疗作用
Regen Ther. 2025 Jun 4;30:123-135. doi: 10.1016/j.reth.2025.05.009. eCollection 2025 Dec.
2
Immunomodulatory effects of canine mesenchymal stem cells in an experimental atopic dermatitis model.犬间充质干细胞在实验性特应性皮炎模型中的免疫调节作用。
Front Vet Sci. 2023 Jul 13;10:1201382. doi: 10.3389/fvets.2023.1201382. eCollection 2023.
3
Extracellular vesicles from IFN-γ-primed mesenchymal stem cells repress atopic dermatitis in mice.

本文引用的文献

1
AIRMESS - Academy of International Regenerative Medicine & Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous stem cell-based therapy (ASC-BT) in androgenetic alopecia and wound healing.AIRMESS - 国际再生医学与外科学会联合会：关于富血小板血浆 (PRP)、自体干细胞为基础的疗法 (ASC-BT) 在雄激素性脱发和伤口愈合中的应用建议。
Expert Opin Biol Ther. 2021 Nov;21(11):1443-1449. doi: 10.1080/14712598.2021.1908995. Epub 2021 Apr 5.
2
Expert consensus on practical aspects in the treatment of chronic urticaria.慢性荨麻疹治疗实践方面的专家共识
Allergo J Int. 2021;30(2):64-75. doi: 10.1007/s40629-021-00162-w. Epub 2021 Feb 24.
3
IFN-γ 预处理的间充质干细胞来源的细胞外囊泡可抑制小鼠特应性皮炎。
J Nanobiotechnology. 2022 Dec 10;20(1):526. doi: 10.1186/s12951-022-01728-8.
Histobulin as a complementary but essential therapeutic for Intravenous Immune Globulin Therapy of Pfeiffer-Weber-Christian disease with multiple allergic diseases and its effects on allergic disease: A case report.
组织球蛋白作为伴有多种过敏性疾病的费弗-韦伯-克里斯蒂安病静脉注射免疫球蛋白治疗的补充性但必不可少的疗法及其对过敏性疾病的影响：一例报告
Clin Case Rep. 2020 Dec 29;9(2):966-972. doi: 10.1002/ccr3.3681. eCollection 2021 Feb.
4
Novel agents for atopic dermatitis in patients over 50 years of age: A case series.50 岁以上特应性皮炎患者的新型药物：病例系列。
Dermatol Ther. 2021 Mar;34(2):e14890. doi: 10.1111/dth.14890. Epub 2021 Feb 23.
5
Immunotherapy using Histobulin in atopic dermatitis.使用组织球蛋白进行特应性皮炎的免疫疗法。
Clin Case Rep. 2020 Nov 11;9(1):113-117. doi: 10.1002/ccr3.3472. eCollection 2021 Jan.
6
Mesenchymal Stem Cells: a Potential Treatment Approach for Refractory Chronic Spontaneous Urticaria.间充质干细胞：治疗难治性慢性自发性荨麻疹的一种潜在方法。
Stem Cell Rev Rep. 2021 Jun;17(3):911-922. doi: 10.1007/s12015-020-10059-w. Epub 2020 Oct 22.
7
Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).大剂量化疗和自体造血干细胞移植患者感染的预防、诊断和治疗。德国血液学和肿瘤学学会（DGHO）感染病工作组（AGIHO）的建议 2020 年更新。
Ann Hematol. 2021 Feb;100(2):321-336. doi: 10.1007/s00277-020-04297-8. Epub 2020 Oct 20.
8
Current and emerging biologics for the treatment of pediatric atopic dermatitis.治疗儿童特应性皮炎的现有和新兴生物制剂。
Expert Opin Biol Ther. 2020 Dec;20(12):1435-1445. doi: 10.1080/14712598.2021.1840548. Epub 2020 Nov 15.
9
Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem Cells (AD-MSCs), Drugs, and Vaccines in Inhibiting COVID-19 Disease.间充质干细胞（MSCs）、脂肪来源间充质干细胞（AD-MSCs）、药物及疫苗在抑制新型冠状病毒肺炎方面的研究进展
Aging Dis. 2020 Oct 1;11(5):1191-1201. doi: 10.14336/AD.2020.0711. eCollection 2020 Oct.
10
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.白细胞介素 6 及其他介质在与 SARS-CoV-2 感染相关的细胞因子风暴中的作用。
J Allergy Clin Immunol. 2020 Sep;146(3):518-534.e1. doi: 10.1016/j.jaci.2020.07.001.